Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000802615 | SCV000942454 | pathogenic | Pyridoxine-dependent epilepsy | 2024-02-15 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 516 of the ALDH7A1 protein (p.Tyr516Cys). This variant is present in population databases (rs200102503, gnomAD 0.1%). This missense change has been observed in individual(s) with pyridoxine-dependent epilepsy (PMID: 29852413, 31737911, 31965297). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 647989). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALDH7A1 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000802615 | SCV002024329 | pathogenic | Pyridoxine-dependent epilepsy | 2021-04-28 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000802615 | SCV004050017 | pathogenic | Pyridoxine-dependent epilepsy | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Juno Genomics, |
RCV000802615 | SCV005415861 | pathogenic | Pyridoxine-dependent epilepsy | criteria provided, single submitter | clinical testing | PM2_Supporting+PP3_Strong+PM3_VeryStrong+PP4 | |
Center of Excellence for Medical Genomics, |
RCV000802615 | SCV002570075 | likely pathogenic | Pyridoxine-dependent epilepsy | 2002-09-08 | no assertion criteria provided | research |